HAS - CERBIOS Inside HAS-Cerbios: Building a unique CDMO Denis Angioletti, Group Head of Commercial & Business Development, framed it in commercial terms. “We can see that we are adding value to what each company was,” he said. “Some customers are now complementing or using what the other company is bringing on board.” Aligning to a fast-growing sector The timing is certainly no accident. The outsourcing of pharmaceutical manufacturing is accelerating as drugs become more complex and costly to produce. Frost & Sullivan estimates the biologics CDMO market grew from $13.3bn in 2018 to $29.3bn in 2022, with projections to reach $100.4bn by 2030. A separate Frost study valued the sector at $21.09bn in 2023 and forecast it would hit $68.97bn by 2031, a compound annual growth rate above 16%. The broader picture is just as striking with Bourne Partners estimating that the global CDMO market will reach around $200bn by 2025, with mid- to highsingle-digit annual growth thereafter. The financial services firm stresses that the top five players hold less than 15% of the market, highlighting its fragmentation and the opportunity for specialists. A new chapter begins in Switzerland’s pharmaceutical services landscape as HAS Healthcare Advanced Synthesis and Cerbios-Pharma join forces under the HAS Group banner, creating a unified front in the CDMO market. Finalised in May of this year, the HAS Group is now in the process of introducing itself into the hearts and minds of its clients, where CPHI presents an opportune moment to familiarize the wider market with the HAS Group identity. The new combined contract development and manufacturing organization (CDMO) will compete globally in oncology, high-potency active pharmaceutical ingredients (HPAPIs), and antibodydrug conjugates (ADCs). For Waldo Mossi, CEO of HAS Group, the deal is about more than scale. “This acquisition is a transformative step,” he told 24/7 BIOPHARMA. “We started the integration phase by creating an executive committee with key management figures from both organizations.” That structure, he explained, allows teams to align across research, production, finance, and business development from day one. 24CPHI FRANKFURT 2025 PREVIEW
RkJQdWJsaXNoZXIy MjY2OTA4MA==